Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer

BACKGROUND: Osimertinib is an essential drug to treat non-small-cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation, and rebiopsy is necessary to detect this mutation. However, the significance of repeat rebiopsy in NSCLC patients whose first rebiopsy was T7...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Ichihara, Eiki, Hotta, Katsuyuki, Kubo, Toshio, Higashionna, Tsukasa, Ninomiya, Kiichiro, Ohashi, Kadoaki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2018
Ämnen:
Clinical Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6047679/
https://ncbi.nlm.nih.gov/pubmed/30034635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25705
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk